The combination of platinum agents with pemetrexed has been the standard-of-care
treatment for unresectable malignant pleural mesothelioma (MPM), although outcomes …

Opinion statement Malignant pleural mesothelioma (MPM) is an aggressive asbestos-
associated thoracic malignancy that is usually incurable. As demonstrated in the landmark …

Simple Summary Platin-based chemotherapy with pemetrexed has been the backbone of
meaningful treatment in pleural mesothelioma for the last 16 years, alongside vinorelbine …

Ahmadzada et al. Biomarkers in mesothelioma who are candidates for surgery undergo
either extra-pleural pneumonectomy (EPP), which involves macroscopic removal of the …

Background Dual immune checkpoint blockers (ICBs) regimen represents a standard first-
line therapy in unresectable pleural mesothelioma (PM). Novel combination strategies …

e20030 Background: Cetuximab is a chimeric monoclonal antibody targeting the epidermal
growth factor receptor (EGFR). Previous studies suggested that cetuximab enhances …

The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the
last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and …

Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the
desperate need to develop better treatment for this disease, the rarity of the tumor type …

Abstract Purpose of Review For patients with malignant pleural mesothelioma, prognosis is
poor with extremely low 5-year survival rates and limited therapeutic options. Here, we …

Malignant pleural mesothelioma (MPM) remains a rare thoracic malignancy with an
incidence in Europe of 1.83 cases per 100 000 individuals annually. 1 Asbestos exposure is …